ribecca: ribociclib, a cdk4/6 inhibitor in er breast cancer
Published 3 years ago • 594 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
8:30
cdk4/6 inhibitors in er metastatic breast cancer during the covid-19 pandemic
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
1:11
unmet needs in the use of cdk4/6 inhibitors in early-stage hr /her2- breast cancer
-
2:31
cdk4/6 inhibitors: a hot topic in breast cancer treatment
-
4:37
case 2: cdk4/6 inhibitors in er breast cancer
-
1:39
frontline endocrine therapies and ribociclib in early stage hr her2- breast cancer
-
3:35
the benefits of adjuvant cdk4/6 and parp inhibition in breast cancer
-
1:12
remaining questions on the use of frontline cdk4/6 inhibitors endocrine therapy
-
0:41
remaining questions regarding the use of front-line cdk4/6 inhibitors in breast cancer
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
1:40
early ribecca results: ribociclib with letrozole for metastatic breast cancer
-
1:07
sequencing first-line cdk4/6 inhibitors in metastatic breast cancer
-
2:38
cdk4/6 inhibitors: the differential value of ribociclib
-
4:17
cdk4/6 inhibitors & endocrine therapy in breast cancer